Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease?
Genre
CorrespondenceDate
2020-10-01Author
Marongiu, FrancescoBarcellona, Doris
Group
Center for Biotechnology, Sbarro Institute for Cancer Research and Molecular Medicine (Temple University)Permanent link to this record
http://hdl.handle.net/20.500.12613/4163
Metadata
Show full item recordDOI
http://doi.org/10.1055/s-0040-1719232Abstract
We have read with interest the review article by Bikdeli et al recently published in Thrombosis and Haemostasis on the priority in planning studies on the different anticoagulants in coronavirus disease 2019 (COVID-19) infection.[1] The authors describe the characteristics of both the anticoagulants available today and in the future. Antiplatelets drugs have been also considered. Surprisingly, fondaparinux (FPX) has reached a lower priority research mean (4.89) than unfractionated heparin (UFH) and low-molecular weight heparin (LMWH) at intermediate (7.82) or therapeutic (7.53) dosage for hospitalized ward and intensive care unit patients. We believe that properties of these drugs have been overlooked by the scientific panel of the Global COVID-19 Thrombosis Collaborative Group.Citation to related work
Georg Thieme Verlag KGHas part
TH Open, Vol. 4, Issue 4ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.eduae974a485f413a2113503eed53cd6c53
http://dx.doi.org/10.34944/dspace/4145